CA2996724C - Compositions comprising urolithin compounds - Google Patents
Compositions comprising urolithin compounds Download PDFInfo
- Publication number
- CA2996724C CA2996724C CA2996724A CA2996724A CA2996724C CA 2996724 C CA2996724 C CA 2996724C CA 2996724 A CA2996724 A CA 2996724A CA 2996724 A CA2996724 A CA 2996724A CA 2996724 C CA2996724 C CA 2996724C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- muscle
- urolithin
- medium
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1515387.7A GB201515387D0 (en) | 2015-08-28 | 2015-08-28 | Compositions |
| GB1515387.7 | 2015-08-28 | ||
| PCT/EP2016/070255 WO2017036992A1 (en) | 2015-08-28 | 2016-08-26 | Compositions comprising urolithin compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2996724A1 CA2996724A1 (en) | 2017-03-09 |
| CA2996724C true CA2996724C (en) | 2024-05-21 |
Family
ID=54326542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2996724A Active CA2996724C (en) | 2015-08-28 | 2016-08-26 | Compositions comprising urolithin compounds |
Country Status (15)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113142581B (zh) * | 2010-12-23 | 2025-07-22 | 阿马曾提斯公司 | 用于改善线粒体功能的组合物和方法 |
| PT2866804T (pt) | 2012-06-27 | 2023-12-18 | Amazentis Sa | Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| EP4553071A3 (en) * | 2017-03-08 | 2025-07-23 | Amazentis SA | Methods for improving mitophagy in subjects |
| US20210267932A1 (en) | 2018-05-15 | 2021-09-02 | University Of Louisville Research Foundation, Inc. | Compounds, compositions, methods of using, and methods for preparing compounds |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| AU2021346837A1 (en) | 2020-09-25 | 2023-03-02 | Société des Produits Nestlé S. A. | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix |
| JP7541673B2 (ja) * | 2020-11-30 | 2024-08-29 | 国立研究開発法人産業技術総合研究所 | 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物 |
| KR102623664B1 (ko) | 2020-12-10 | 2024-01-12 | 서울대학교산학협력단 | 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법 |
| US11820751B2 (en) | 2021-01-27 | 2023-11-21 | Vandria Sa | Urolithin derivatives and methods of use thereof |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| CN113813255B (zh) * | 2021-10-20 | 2023-09-01 | 山东大学 | 尿石素a及其衍生物在肿瘤免疫治疗的应用 |
| JPWO2023199908A1 (cg-RX-API-DMAC10.html) * | 2022-04-11 | 2023-10-19 | ||
| GB202219317D0 (en) * | 2022-12-20 | 2023-02-01 | Amazentis Sa | Methods for improving mitophagy in subjects |
| WO2024142098A1 (en) * | 2022-12-27 | 2024-07-04 | Indian Institute Of Science | A method for the treatment of epilepsy |
| GB202308224D0 (en) | 2023-06-01 | 2023-07-19 | Amazentis Sa | Formulation |
| GB202316295D0 (en) | 2023-10-24 | 2023-12-06 | Amazentis Sa | Composition |
| EP4555997A1 (en) * | 2023-11-15 | 2025-05-21 | Science4Beauty Sp. z o.o. | Water-soluble composition comprising urolithin |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
| KR20250158913A (ko) | 2024-04-30 | 2025-11-07 | 주식회사 파이안바이오테크놀로지 | 유로리틴을 함유하는 탈모완화제와 모발성장촉진제 |
| WO2025252771A1 (en) | 2024-06-03 | 2025-12-11 | Amazentis Sa | Urolithin combinations |
| GB202416802D0 (en) | 2024-11-14 | 2025-01-01 | Amazentis Sa | Urolithin combination |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| JP2000507268A (ja) | 1996-03-26 | 2000-06-13 | イーライ・リリー・アンド・カンパニー | ベンゾチオフェン類、それを含む製剤、および方法 |
| WO1999053941A1 (fr) * | 1998-04-15 | 1999-10-28 | Shionogi & Co., Ltd. | Preparations orales contenant des derives de trh |
| DE60038097T2 (de) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
| US20050282781A1 (en) * | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| JP5147239B2 (ja) | 2004-09-29 | 2013-02-20 | 三栄源エフ・エフ・アイ株式会社 | コエンザイムｑ１０含有乳化組成物 |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| US8894993B2 (en) * | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| EP2145904A1 (de) | 2008-07-18 | 2010-01-20 | Basf Se | Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen |
| RU2678833C2 (ru) | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| CN104016951B (zh) | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
| PL2550092T3 (pl) | 2010-03-22 | 2019-01-31 | Instillo Gmbh | Sposób wytwarzania mikro- lub nanocząstek |
| BR112012026843A2 (pt) | 2010-04-20 | 2016-07-12 | Cipla Ltd | composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv |
| JP2013544829A (ja) | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法 |
| JP2012111712A (ja) | 2010-11-25 | 2012-06-14 | Toyo Capsule Kk | 油性ビタミンｃ経口投与用組成物 |
| CN113142581B (zh) * | 2010-12-23 | 2025-07-22 | 阿马曾提斯公司 | 用于改善线粒体功能的组合物和方法 |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION |
| US20140079729A1 (en) * | 2012-09-14 | 2014-03-20 | Natreon, Inc. | Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit |
| GB201323008D0 (en) * | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
-
2015
- 2015-08-28 GB GBGB1515387.7A patent/GB201515387D0/en not_active Ceased
-
2016
- 2016-08-26 CA CA2996724A patent/CA2996724C/en active Active
- 2016-08-26 KR KR1020187007291A patent/KR102660005B1/ko active Active
- 2016-08-26 SG SG10202001793PA patent/SG10202001793PA/en unknown
- 2016-08-26 PT PT167572635T patent/PT3340977T/pt unknown
- 2016-08-26 BR BR112018003745-1A patent/BR112018003745B1/pt active IP Right Grant
- 2016-08-26 MX MX2018002543A patent/MX2018002543A/es unknown
- 2016-08-26 EP EP16757263.5A patent/EP3340977B1/en active Active
- 2016-08-26 KR KR1020247012842A patent/KR102822365B1/ko active Active
- 2016-08-26 JP JP2018529732A patent/JP7227003B2/ja active Active
- 2016-08-26 AU AU2016314987A patent/AU2016314987B2/en active Active
- 2016-08-26 CN CN201680050456.6A patent/CN108289879B/zh active Active
- 2016-08-26 ES ES16757263T patent/ES2936723T3/es active Active
- 2016-08-26 WO PCT/EP2016/070255 patent/WO2017036992A1/en not_active Ceased
- 2016-08-26 US US15/757,293 patent/US10695320B2/en active Active
- 2016-08-26 RU RU2018108136A patent/RU2754761C2/ru active
-
2020
- 2020-06-15 US US16/901,182 patent/US11337957B2/en active Active
-
2022
- 2022-05-05 US US17/737,605 patent/US11925616B2/en active Active
- 2022-09-12 JP JP2022144671A patent/JP2022177130A/ja active Pending
-
2024
- 2024-01-19 US US18/417,794 patent/US20240148690A1/en not_active Abandoned
- 2024-10-04 JP JP2024174863A patent/JP2025004129A/ja active Pending
-
2025
- 2025-08-26 US US19/310,137 patent/US20260216125A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11925616B2 (en) | Compositions comprising urolithin compounds | |
| AU2021201143B2 (en) | Compositions comprising an urolithin compound | |
| JP2023100869A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| JP2023100870A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| JP2019182881A (ja) | 末梢神経障害の予防又は改善用組成物 | |
| JP6675413B2 (ja) | トコトリエノールを効果的に送達するための製剤 | |
| AU2023410424A1 (en) | Combinations of a urolithin and a ketone body | |
| HK1257500B (en) | Compositions comprising urolithin compounds | |
| JPWO1996022102A1 (ja) | 皮膚炎治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210825 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260702 |